Caveolin-1 Modulates the Ability of Ewing's Sarcoma to Metastasize

Metastasis is the final stage of tumor progression and is thought to be responsible for up to 90% of deaths associated with solid tumors. Caveolin-1 (CAV1) regulates multiple cancer-associated processes related to malignant tumor progression. In the present study, we tested the hypothesis that CAV1 modulates the metastatic ability of cells from the Ewing's sarcoma family of tumors (ESFT). First, we analyzed the expression of CAV1 by immunostaining a tissue microarray containing 43 paraffin-embedded ESFT tumors with known EWS translocations. Even though no evidence was found for a significant association between CAV1 expression and stage, size or tumor site, all metastatic samples (10 of 10) had significantly high CAV1 expression, suggesting that high CAV1 content could positively contribute to enhance ESFT metastasis. To determine the effect of CAV1 on the migratory and invasive capabilities of ESFT cells, we knocked down CAV1 expression in TC252 and A673 cells by stably transfecting a previously validated shRNA construct. In vitro, migration and invasion assays showed that for both cell lines, CAV1 knocked-down cells migrated and invaded significantly less (P ≤ 0.01) than control cells. Moreover, control A673 cells introduced into BALB/c nude mice by tail vein injection strongly colonized the lungs. In contrast, animals injected with CAV1 knocked-down cells showed either no incidence of metastasis or developed lung metastases after a significant delay (P < 0.0001). Finally, we show that the molecular mechanisms by which CAV1 carries out its key role in regulating ESFT metastasis involve matrix metalloproteinase production and activation as well as the control of the expression of SPARC, a known determinant of lung colonization. Mol Cancer Res; 8(11); 1489–500. ©2010 AACR.

[1]  Hong Zhu,et al.  Caveolin-1 regulating the invasion and expression of matrix metalloproteinase (MMPs) in pancreatic carcinoma cells. , 2010, The Journal of surgical research.

[2]  S. Cohn,et al.  Modulation of matrix remodeling by SPARC in neoplastic progression. , 2010, Seminars in cell & developmental biology.

[3]  P. Lollini,et al.  High metastatic efficiency of human sarcoma cells in Rag2/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy. , 2010, European journal of cancer.

[4]  C. MacCarthy,et al.  Caveolin‐1 promotes resistance to chemotherapy‐induced apoptosis in Ewing's sarcoma cells by modulating PKCα phosphorylation , 2010, International journal of cancer.

[5]  Shuhei Yoshida,et al.  Lipid rafts and caveolin-1 are required for invadopodia formation and extracellular matrix degradation by human breast cancer cells. , 2009, Cancer research.

[6]  Rolf A. Brekken,et al.  SPARC: a matricellular regulator of tumorigenesis , 2009, Journal of Cell Communication and Signaling.

[7]  M. Biffoni,et al.  Caveolin‐1 tumor‐promoting role in human melanoma , 2009, International journal of cancer.

[8]  Paula D. Bos,et al.  Metastasis: from dissemination to organ-specific colonization , 2009, Nature Reviews Cancer.

[9]  H. Kovar,et al.  EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation , 2009, Proceedings of the National Academy of Sciences.

[10]  M. Tang,et al.  SPARC in cancer biology: its role in cancer progression and potential for therapy. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[11]  Steven J. M. Jones,et al.  Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion. , 2008, Cancer research.

[12]  M. Ebert,et al.  Caveats of caveolin-1 in cancer progression. , 2008, Cancer letters.

[13]  D. Chuderland,et al.  Filamin A is a novel caveolin-1-dependent target in IGF-I-stimulated cancer cell migration. , 2008, Experimental cell research.

[14]  D. Edwards,et al.  The regulation of matrix metalloproteinases and their inhibitors. , 2008, The international journal of biochemistry & cell biology.

[15]  S. Wiseman,et al.  Caveolin-1 in tumor progression: the good, the bad and the ugly , 2008, Cancer and Metastasis Reviews.

[16]  A. Chakraborty,et al.  Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis , 2008, Nature Reviews Cancer.

[17]  Gema Moreno-Bueno,et al.  Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. , 2008, Cancer research.

[18]  Erik Sahai,et al.  Illuminating the metastatic process , 2007, Nature Reviews Cancer.

[19]  J. Massagué,et al.  Genetic determinants of cancer metastasis , 2007, Nature Reviews Genetics.

[20]  A. Sánchez-Aguilera,et al.  A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. , 2007, Cancer research.

[21]  V. Soldatenkov,et al.  Combined Transcriptional and Translational Targeting of EWS/FLI-1 in Ewing's Sarcoma , 2006, Clinical Cancer Research.

[22]  J. Ban,et al.  Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells. , 2006, Cancer research.

[23]  K. V. van Golen.  Is caveolin-1 a viable therapeutic target to reduce cancer metastasis? , 2006, Expert opinion on therapeutic targets.

[24]  K. Golen.  Is caveolin-1 a viable therapeutic target to reduce cancer metastasis? , 2006 .

[25]  C. Rodríguez-Galindo,et al.  STAT3 is activated in a subset of the Ewing sarcoma family of tumours , 2006, The Journal of pathology.

[26]  C. Malvy,et al.  Oncogene-targeted antisense oligonucleotides for the treatment of Ewing sarcoma , 2005, Expert opinion on therapeutic targets.

[27]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[28]  John N. Hutchinson,et al.  Caveolin-1 Gene Disruption Promotes Mammary Tumorigenesis and Dramatically Enhances Lung Metastasis in Vivo , 2004, Journal of Biological Chemistry.

[29]  M. Parat,et al.  A role for caveolae in cell migration , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  Y. St-Pierre,et al.  Regulation of MMP-9 gene expression for the development of novel molecular targets against cancer and inflammatory diseases , 2004, Expert opinion on therapeutic targets.

[31]  Y. DeClerck,et al.  TIMP-2 is released as an intact molecule following binding to MT1-MMP on the cell surface. , 2004, Experimental cell research.

[32]  H. Kovar,et al.  Potentials for RNAi in sarcoma research and therapy: Ewing's sarcoma as a model. , 2003, Seminars in cancer biology.

[33]  Y. Toyama,et al.  Lack of matrix metalloproteinase (MMP)-1 and -3 expression in Ewing sarcoma may be due to loss of accessibility of the MMP regulatory element to the specific fusion protein in vivo. , 2002, Biochemical and biophysical research communications.

[34]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[35]  Hiroshi Sato,et al.  Homophilic complex formation of MT1‐MMP facilitates proMMP‐2 activation on the cell surface and promotes tumor cell invasion , 2001, The EMBO journal.

[36]  D. Lauffenburger,et al.  Cell Migration: A Physically Integrated Molecular Process , 1996, Cell.

[37]  M. Lippman,et al.  Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. , 1993, Journal of the National Cancer Institute.

[38]  G. Thomas,et al.  Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours , 1992, Nature.

[39]  A. Cabrera,et al.  EWING'S SARCOMA. , 1964, Surgery, gynecology & obstetrics.

[40]  C. López-Otín,et al.  Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. , 2010, Biochimica et biophysica acta.

[41]  E. Lander,et al.  A molecular signature of metastasis in primary solid tumors , 2003, Nature Genetics.